Results 31 to 40 of about 177 (68)

Antifungal metabolites, their novel sources, and targets to combat drug resistance. [PDF]

Front Microbiol, 2022
Choudhary M, Kumar V, Naik B, Verma A, Saris PEJ, Kumar V, Gupta S.   +6 more
europepmc   +1 more source

In Vivo Efficacy of Olorofim against Systemic Scedosporiosis and Lomentosporiosis. [PDF]

Antimicrob Agents Chemother, 2021
Seyedmousavi S, Chang YC, Youn JH, Law D, Birch M, Rex JH, Kwon-Chung KJ.   +6 more
europepmc   +1 more source

Repurposing and optimization of drugs for discovery of novel antifungals. [PDF]

Drug Discov Today, 2022
Donlin MJ, Meyers MJ.
europepmc   +1 more source

Novel Antifungal Agents and Their Activity against <i>Aspergillus</i> Species. [PDF]

J Fungi (Basel), 2020
Vahedi-Shahandashti R, Lass-Flörl C.
europepmc   +1 more source

Advances in anti-fungal therapies. [PDF]

Mycopathologia, 2021
Waterer G.
europepmc   +1 more source

New trends in antifungal treatment: What is coming up? [PDF]

Rev Esp Quimioter, 2023
Guinea J.
europepmc   +1 more source

Successful use of olorofim for the treatment of <i>Lomentospora prolificans</i> knee tendonitis, synovitis, and concomitant osteomyelitis in an immunocompetent child. [PDF]

Antimicrob Agents Chemother
Fortini M, Jones TW, Grams TR, Mehra S.
europepmc   +1 more source

Novel Promising Antifungal Target Proteins for Conquering Invasive Fungal Infections. [PDF]

Front Microbiol, 2022
Zhen C, Lu H, Jiang Y.
europepmc   +1 more source

A quiet but growing threat: Global perspectives on antifungal resistance and future therapeutic approaches. [PDF]

Indian J Pharmacol
Gurajala S, Challapilla M.
europepmc   +1 more source

Case Commentary: Successful use of olorofim for the treatment of multi-drug-resistant <i>Lomentospora prolificans</i> infection in a child. [PDF]

Antimicrob Agents Chemother
Wiederhold NP.
europepmc   +1 more source